AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): One of the most well-established impacts of high salt intake is its association with hypertension. Excess sodium in the diet can lead to fluid retention and increased blood volume, putting pressure on the blood vessel walls and raising blood pressure. Persistent high blood pressure is a significant risk factor for cardiovascular diseases like heart disease, stroke, and kidney disease.
Cardiovascular Diseases: High salt intake is linked to an increased risk of developing cardiovascular diseases, including coronary artery disease, heart attack, and stroke. Excessive sodium consumption can contribute to the development of atherosclerosis (hardening and narrowing of the arteries), which can lead to heart disease and stroke.
Kidney Disease: The kidneys play a crucial role in regulating sodium balance in the body. High salt intake can put strain on the kidneys, potentially leading to kidney damage over time. Individuals with existing kidney disease or impaired kidney function may be particularly sensitive to the effects of high salt intake.
Fluid Retention and Edema: Excess sodium in the body can cause fluid retention, leading to swelling or edema, particularly in the ankles, feet, and hands. This can be especially problematic for individuals with conditions like heart failure or kidney disease, where fluid retention can exacerbate symptoms and complications.
Osteoporosis: Some research suggests that high salt intake may be associated with decreased bone density and an increased risk of osteoporosis. Excessive sodium consumption may lead to increased urinary calcium excretion, potentially contributing to bone loss
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
ADHD | 0.6 | 0.2 | 2 |
Age-Related Macular Degeneration and Glaucoma | 0.7 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.7 | 0.7 | |
Allergies | 1.1 | 0.1 | 10 |
Allergy to milk products | 0.6 | 0.2 | 2 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 0.7 | 0.9 | -0.29 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.3 | 1.33 |
Ankylosing spondylitis | 0.9 | 0.4 | 1.25 |
Anorexia Nervosa | 0 | 0.7 | 0 |
Antiphospholipid syndrome (APS) | 1.5 | 0 | 0 |
Asthma | 0.1 | 0.5 | -4 |
Atherosclerosis | 1.2 | -1.2 | |
Atrial fibrillation | 0.8 | 0.3 | 1.67 |
Autism | 2.8 | 2.3 | 0.22 |
Barrett esophagus cancer | 0.1 | -0.1 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.3 | 0.6 | -1 |
Brain Trauma | 0.5 | -0.5 | |
Carcinoma | 0.8 | 0.6 | 0.33 |
Celiac Disease | 1.3 | 0.6 | 1.17 |
Cerebral Palsy | 0.2 | 0.5 | -1.5 |
Chronic Fatigue Syndrome | 1.3 | 2.8 | -1.15 |
Chronic Kidney Disease | 0.5 | 0.6 | -0.2 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.6 | -2 |
Chronic Urticaria (Hives) | 0.6 | 0.6 | |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.4 | 0.25 |
Colorectal Cancer | 1.1 | 1.1 | |
Constipation | 1.1 | 0.4 | 1.75 |
Coronary artery disease | 0.2 | 0.2 | 0 |
COVID-19 | 2.2 | 4.2 | -0.91 |
Crohn's Disease | 2.2 | 1.1 | 1 |
cystic fibrosis | 0.4 | 0.5 | -0.25 |
deep vein thrombosis | 0.4 | 0.4 | 0 |
Depression | 2.1 | 2.2 | -0.05 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.4 | 0.3 | 0.33 |
Endometriosis | 1.2 | 1.2 | |
Epilepsy | 0.4 | 0.2 | 1 |
Fibromyalgia | 0.9 | 0.9 | 0 |
Functional constipation / chronic idiopathic constipation | 2.3 | 0.9 | 1.56 |
gallstone disease (gsd) | 0.7 | 0.4 | 0.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.1 | 7 |
Generalized anxiety disorder | 0.7 | 0.5 | 0.4 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.2 | 0.7 | -2.5 |
Halitosis | 0.1 | 0.1 | 0 |
Hashimoto's thyroiditis | 0.9 | 0.2 | 3.5 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.1 | 11 |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
hyperglycemia | 0.1 | 0.2 | -1 |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 0.4 | 0.8 | -1 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 1 | -1 | |
Inflammatory Bowel Disease | 1 | 1.6 | -0.6 |
Insomnia | 0.2 | 0.5 | -1.5 |
Intelligence | 0.6 | 0.6 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1.5 | 1.6 | -0.07 |
Liver Cirrhosis | 1.5 | 1.3 | 0.15 |
Long COVID | 2.2 | 1.5 | 0.47 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 0.1 | 0.4 | -3 |
ME/CFS with IBS | 0.2 | 1.3 | -5.5 |
ME/CFS without IBS | 0.6 | 1.3 | -1.17 |
Metabolic Syndrome | 2 | 2.4 | -0.2 |
Mood Disorders | 2.7 | 2.2 | 0.23 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 0.6 | 1 | -0.67 |
Neuropathy (all types) | 0.1 | 0.1 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.3 | 1.33 |
Obesity | 2.5 | 1.5 | 0.67 |
obsessive-compulsive disorder | 1.7 | 1 | 0.7 |
Osteoarthritis | 0.7 | 0.7 | |
Osteoporosis | 0.4 | 0.1 | 3 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 0.6 | 1.5 | -1.5 |
Polycystic ovary syndrome | 1.3 | 0.5 | 1.6 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.2 | -1 |
Premenstrual dysphoric disorder | 0 | 0 | |
primary biliary cholangitis | 0.4 | 0.2 | 1 |
Psoriasis | 1.3 | 0.7 | 0.86 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 1.2 | 0.33 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 1.1 | 0.7 | 0.57 |
scoliosis | 0.2 | 0 | 0 |
Sjögren syndrome | 0.2 | 0.8 | -3 |
Sleep Apnea | 0.2 | 0.7 | -2.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 1.4 | 0.7 | 1 |
Systemic Lupus Erythematosus | 0.8 | 0.4 | 1 |
Tic Disorder | 0.8 | 0.4 | 1 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1.4 | 1.4 | 0 |
Type 2 Diabetes | 2.7 | 3 | -0.11 |
Ulcerative colitis | 1.5 | 2 | -0.33 |
Unhealthy Ageing | 1.5 | 0.6 | 1.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.